Endotis Pharma

Endotis Pharma is a biotech-pharma company created in 2003 and specializes in the discovery and development of small glycan drugs (SGDs). Their properties (solubility, stability, metabolism…) provide SGDs a number of key advantages over other therapeutics, yet, probably due to the difficulty of their chemistry, it is only recently that the pharmaceutical industry has begun to exploit this great potential; the anti-thrombotics Fondaparinux and Idraparinux, for instance, are derived from heparin. Through internal research and in-licensing, Endotis has developed a solid, innovative and very promising thrombosis pipeline, with a first candidate entering phase II (indication: acute coronary syndrom) and two others entering Phase I.


Recent News

November 15, 2010
Endotis Pharma reports successful completion of the neutralization study of the anticoagulant EP217609 by avidin in healthy subjects

 
May 19, 2009
Endotis Pharma reports successful completion of phase I program with EP42675, a first in class synthetic parenteral anticoagulant

 
January 23, 2008
Endotis Pharma Raises €25 million in a Second Financing Round

 


Company Info
 
Country: France
Industry:    LS
Sector: biotechnology
Status: Unrealized
Vehicle: Endeavour II LP


Key persons
 Charles Woler, CEO


Company website
 www.endotis.com


Endeavour Vision Team
 
Olivier Valdenaire
Sven Lingjaerde
© Endeavour Vision SA 2006-2013 Terms & Conditions